Accomplished and motivated cancer cell biologist with 10+ years of combined industry and academia experience in oncology small molecule drug discovery and translational work. With expertise and strong track record of publication in genomic integrity and synthetic lethality. Lead player in cross-functional team focusing on DDR portfolio, including PARP inhibitor-centric projects and new DDR target identification and validation.